تحليل اغلاق يوم الجمعة 14 يناير مع توصيات

[بو معاذ]

Today’s Overview

The index futures bounced off the lows and back into the persistent range. Most
of the action was over after the first hour of trading. Volume was light ahead of
the long holiday weekend. The weekly close shows spinning top candles on the
major indices, reflecting indecision and confusion.
Next week is options expiration. The overriding bearish sentiment should keep a
floor under the market during this period. There is also a chance we’ll finally see
a climax of the hedging themes brought into play last month. At least that’s my
theory for now.


علما بأن شركة Viacell ستطرح يوم الخميس و تملك Amgen نسبة بها و فيما يلي ملخص عن الشركة
ViaCell, Inc
A biotechnology company developing a novel cell expansion technology


131 Clarendon Street
Boston, MA 02116
Telephone: 617-603-4600
Facsimile: 617-266-3953
Web: http://www.viacellinc.com
Edgar: SEC Filings CEO: Marc D. Beer
CFO: Stephen G. Dance
Sector: Healthcare
Industry: Biotechnology & Drugs
SIC Code: 8731 - Commercial Physical and Biological Research


Filed: 04/05/04
(Previous filing on 01/30/02; was withdrawn on 12/31/03)


ViaCell, Inc. is a global biotechnology company engaged in sourcing, developing and commercializing cellular therapies to address cancer, infertility, and certain genetic and cardiac diseases. ViaCell’s mission is to enable the widespread application of human cells as medical therapy. Cellular therapy already has a significant role in the treatment of human disease. For example, in 2002, over 45,000 bone marrow and other hematopoietic (blood) stem cell transplant procedures were performed worldwide. Researchers generally acknowledge the far-reaching potential of stem cells to treat many serious diseases that currently afflict an estimated 50 million Americans. However, the potential of cellular therapy has been largely unrealized. Current sources of stem cells are difficult to harvest and typically yield a poorly characterized mixture of cells with an insufficient quantity of the therapeutic stem cells. In addition, compatible donors are often not found. We believe we have the infrastructure in place in research, sourcing, development, manufacturing and marketing, combined with proprietary technologies and strategic partnerships, to overcome these limitations. Our lead stem cell product candidate, CB001, is manufactured using one of our proprietary technologies which allows the isolation, purification and significant expansion of populations of stem cells. We believe this proprietary technology will enable the production of well defined cellular products in therapeutically useful quantities. We are developing CB001 for use in bone marrow and other hematopoietic stem cell transplants. We are further leveraging our infrastructure in cellular therapy to develop a pipeline of products for a range of unmet medical needs. Our current commercialized product is Viacord, a leading brand in the cryopreservation of umbilical cord blood stem cells, which are primarily used for pediatric bone marrow transplants. We intend to use umbilical cord blood, an abundant and non-controversial source of stem cells, as the source of material for our stem cell products, if successfully developed. In addition, we are developing a product intended to offer women the ability to preserve their fertility through the proprietary application of a naturally occurring sugar, which acts as a cryopreservative, to human oocytes (eggs).

Securities Offered: Common Stock
Symbol: VIAC Exchange: Nasdaq NM
Number of Shares Offered: 7,500,000 (by company)
0 (by shareholders)
Shares Outstanding: 36,072,518 (after offering)
Offering Price: N/A Est. Amount Raised $92.0 Mil.
Filing Price: $7.00 - 9.00
Underwriter(s): CS First Boston, UBS Investment Bank, Lazard, Leerink Swann & Company

[من نجد]

يعطيك العافية ، نزيد عليك أخي مقتطف مهم من نقرير عرض وطلب
تطلعات
لقد رجّح الاحتياطي الفدرالي الأميركي في آخر بيان رسمي له أن تزداد نسبة التضخم في ظل التدني الذي يشهده الدولار، وأكّد على ضرورة رفع سعر الفائدة لمحاربة هذا التضخم. إلا أن انخفاض مؤشر سعر المنتج (ppi) في شهر ديسمبر إلى أدنى مستوى له منذ 20 شهراً يدلّ على أن شبح التضخم لا يتربّص بالاقتصاد الأميركي البتة. ومن المنتظر أن يؤكّد على ذلك بيان مؤشر سعر المستهلك (cpi) الذي يصدر يوم الأربعاء، والذي يعتبر بدوره مؤشراً لمعدّل التضخّم. ومع ذلك، فإن البنك المركزي لن يعدل على الأرجح عن سياسة شد الأحزمة، ومن المتوقع أن يرفع سعر الفائدة من 2.25% إلى 2.50% خلال اجتماعه المقبل في 2 فبراير .
سنرى ماذا يحدث